Freedom Capital Markets keeps Omada Health at Buy and starts Newsmax at Hold
Freedom Capital Markets kept Omada Health at Buy with a $35 target and initiated Newsmax at Hold with a $10 target, according to Benzinga data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Freedom Capital Markets maintained its Buy rating on Omada Health (OMDA) and set a $35 price target for the shares.
Separately, the same firm started coverage of Newsmax (NMAX) with a Hold rating and a $10 target.
The information comes from Benzinga, which logged both actions on October 14, 2026, at 19:33 and 21:06 GMT.
why it matters
Updates like these show how one brokerage views the prospects of two companies, but they do not change reported financial results. A single firm's rating and target reflect its own opinion and are not a forecast or a recommendation to trade.
tags
instruments
sources
- Omada Health Price Target Maintained With a $35.00/Share by Freedom Capital Markets — Newsmetry API, 14 October 2026 at 19:33 UTC
- Newsmax Price Target Announced at $10.00/Share by Freedom Capital Markets — Newsmetry API, 14 October 2026 at 21:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗